Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05923983
Other study ID # 2019_1030
Secondary ID 2021-A03211-40AA
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2023
Est. completion date July 2024

Study information

Verified date June 2023
Source University Hospital, Lille
Contact Jean-Baptiste Beuscart, MD
Phone 0320445962
Email jean-baptiste.beuscart@univ-lille.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Current evidence shows that computerized decision support systems (CDSS) have shown to be insufficiently effective to prevent adverse drug reactions (ADRs) at large scale (e.g. whole hospital). Several barriers for successful implementation of CDSS have been identified: over-alerting, lack of specificity of rules, and physician interruption during prescription. The effectiveness of CDSS could be increased in two ways. Firstly, by creating rules that are more specific to a given adverse drug reaction: the current study focuses on acute renal failure and hyperkalemia (two serious and frequent ADR in older hospitalized patients). Secondly, by involving the pharmacist in the review of the alerts so that he/she can transmit, if deemed necessary, a pharmaceutical recommendation to the clinician. This procedure will reduce over-alerting and prevent task interruption. The hypothesis is that the use of specific rules created by a multidisciplinary team and implemented in a CDSS, combined with a strategy for managing and transmitting alerts, can reduce specific ADRs such as hyperkalemia and acute renal failure.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 4920
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Hospitalized for 3 days or more in an MCO (medicine surgery obstetrics) department participating in the study - Patient who gave oral consent to participate in the study - Socially insured patient Exclusion Criteria: - Patient discharged or died before D3 of hospitalization - Patient in palliative care or end of life on entry to the service - Person under legal protection (curatorship) - Lack of coverage by the social security system, Failure to obtain oral consent to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Clinical decision support
In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
Will not receive Clinical Decision Support
In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Lille OméDIT (Observatory of Medicines, Medical Devices and Therapeutic Innovations, Regional Agency of Sante Nord Pas-de-Calais

Outcome

Type Measure Description Time frame Safety issue
Primary Number of adverse drug events such as acute renal failure and/or hyperkalemia in older hospitalized patients. through study completion, an average of 20 days
Secondary Presence of an adverse event related to the intervention provided ("change of prescription", "discontinuation of drug") through study completion, an average of 20 days
Secondary Therapeutic adaptations implemented in case of acute renal failure (ARF) or hyperkalemia upon hospital admission Therapeutic changes within 72 hours of a CDSS alert for acute renal failure or hyperkalemia. Therapeutic changes include discontinuation of drug therapy, introduction of a new drug, dose reduction or change of drug through study completion, an average of 15 days
Secondary Relevance of CDSS alerts Relevance of CDSS alerts is defined in a standard way. Each CDSS alert is evaluated by a clinical pharmacist according to their own expertise and data available in the EHR. If the alert was deemed not relevant, the clinical pharmacist did not perform any pharmaceutical intervention. The CDSS software register the classification of the alert as "not relevant". This approach was used the last 4 years in our hospital and as been published in an article published in the International Journal of Medical Informatics: Cuvelier E, Robert L, Musy E, Rousselière C, Marcilly R, Gautier S, Odou P, Beuscart JB, Décaudin B. The clinical pharmacist's role in enhancing the relevance of a clinical decision support system. Int J Med Inform. 2021 Nov;155:104568. doi: 10.1016/j.ijmedinf.2021.104568. Epub 2021 Sep 2. PMID: 34537687 through study completion, an average of 20 days
Secondary Number of pharmaceutical interventions accepted When an alert is received by the pharmacist, it is analyzed and the pharmacist forwards a pharmaceutical intervention to the physician in charge of the patient to propose a modification of the treatment (dosage, dose, stop through study completion, an average of 20 days
Secondary Changes in ADEs (Adverse Drug Event) prevention/management work process induced by the introduction of alerts Changes in the work system are identified through a comparison of its elements (tools, tasks, organization, interactions, work environment, professionals), before and after the introduction of alerts, using qualitative system engineering methods. Through study completion, an average of 20 days
Secondary Cost-effectiveness of the pharmaceutical intervention Use medico-economic data such as time spent treating an alert, cost of treating an adverse drug reaction to estimate the cost-effectiveness of the intervention through study completion, an average of 20 days
See also
  Status Clinical Trial Phase
Completed NCT01946113 - Mineral-Homeostasis in Continuous Renal Replacement Therapy N/A
Withdrawn NCT00993733 - Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Terminated NCT00978354 - Furosemide in Early Acute Kidney Injury Phase 2/Phase 3
Completed NCT00120263 - Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma N/A
Completed NCT04799600 - The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT02858531 - Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
Recruiting NCT05282732 - Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
Completed NCT01467466 - Prevention of Serious Adverse Events Following Angiography Phase 3
Completed NCT01979042 - Urinary Markers for Unilateral Kidney Obstruction N/A
Completed NCT01280617 - Low Dose Thymoglobin in Renal Transplant Patients N/A
Completed NCT00780351 - Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f) N/A
Completed NCT00971971 - Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients N/A
Completed NCT00076219 - Acute Renal Failure Trial Network (ATN) Study Phase 3
Recruiting NCT04599569 - Influence of Renal Replacement TherApy on Indirect Calorimetry
Completed NCT03727204 - Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
Completed NCT06005896 - A Clinical Model for Dialysis Discontinuation in AKI
Completed NCT03004950 - Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
Completed NCT03627884 - Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation Phase 4